Evidence map›Paper›PMID 30822435›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2019

Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating inflammation.

Eiji Saito, Robert Kuo, Ryan M Pearson, Nishant Gohel, Brandon Cheung, Nicholas J C King, Stephen D Miller, Lonnie D Shea

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 103 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Nanoparticle and epothilone D combinatorial intervention improves motor performance and regeneration in chronic cervical spinal cord injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Eiji SaitoDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Robert KuoDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Ryan M PearsonDepartment of Pharmaceutical Sciences, University of Maryland, Baltimore, MD 21201, USA.
Nishant GohelDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Brandon CheungDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Nicholas J C KingThe Discipline of Pathology, School of Medical Science, Bosch Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales 2006, Australia.
Stephen D MillerDepartment of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; Chemistry of Life Processes Institute (CLP), Northwestern University, Evanston, IL 60208, USA; The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA. Electronic address: s-d-miller@northwestern.edu.
Lonnie D SheaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: ldshea@umich.edu.
University of Michigan–Ann Arbor · USNorthwestern University · USUniversity of Maryland, Baltimore · USUniversity of Sydney · AU

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Antigen Loaded Particles for Tolerance InductionR01EB013198 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MILLER, STEPHEN D, SHEA, LONNIE D · 2011 to 2018
$4.1M
Chemistry of Life Processes Predoctoral Training ProgramT32GM105538 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2013 to 2022
$2.7M
Regulation of CD4+ T cell-mediated Demyelination Following Oligo AblationR01NS099334 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MILLER, STEPHEN D, POPKO, BRIAN J · 2017 to 2021
$2.1M
NIBIB NIH HHS R01 EB013198NIDDK NIH HHS P30 DK020572NIGMS NIH HHS T32 GM105538NINDS NIH HHS R01 NS099334
6 · The paper itself

Abstract

Inflammation associated with autoimmune diseases and chronic injury is an initiating event that leads to tissue degeneration and dysfunction. Inflammatory monocytes and neutrophils systemically circulate and enter inflamed tissue, and pharmaceutical based targeting of these cells has not substantially improved outcomes and has had side effects. Herein, we investigated the design of drug-free biodegradable nanoparticles, notably without any active pharmaceutical ingredient or targeting ligand, that target circulating inflammatory monocytes and neutrophils in the vasculature to inhibit them from migrating into inflamed tissue. Nanoparticles were formed from 50:50 poly(DL-lactide-co-glycolide) (PLG) with two molecular weights (Low, High) and poly(DL-lactide) (PLA) (termed PLG-L, PLG-H, and PDLA, respectively) and were analyzed for their association with monocytes and neutrophils and their impact on disease course along with immune cell trafficking. For particles injected intravenously for 6 consecutive days to mice with experimental autoimmune encephalomyelitis (EAE), PLG-H particles had significantly lower EAE clinical scores than PBS control, while PLG-L and PDLA particles had modest or negligible effect on EAE onset. In vivo and in vitro data suggests that PLG-H particles had high association with immune cells, with preferential association with blood neutrophils relative to other particles. PLG-H particles restrained immune cells from the central nervous system (CNS), with increased accumulation in the spleen, which was not observed for mice receiving PDLA or control treatments. These results demonstrate that the particle composition influences the association with inflammatory monocytes and neutrophils in the vasculature, with the potential to redirect trafficking and ameliorate inflammation.

Indexed as

AnimalsEncephalomyelitis, Autoimmune, ExperimentalFemaleInflammationMiceMonocytesMyelin Proteolipid ProteinNanoparticlesNeutrophilsPeptide FragmentsPolyestersPolylactic Acid-Polyglycolic Acid CopolymerSpleenMyelin Proteolipid Proteinmyelin proteolipid protein (139-151)Peptide FragmentsPolyestersPolylactic Acid-Polyglycolic Acid Copolymerpoly(lactide)InflammationMonocytesNanomedicineNeutrophilsPoly(lactide-co-glycolide) nanoparticles

Identifiers

PMID30822435
PMCPMC6486651
OpenAlexW2915498411

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.